- Home
- ECPG vs SYRE Comparison
ECPG vs SYRE Comparison
Compare ECPG & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECPG
- SYRE
- Stock Information
- Founded
- ECPG 1998
- SYRE 2013
- Country
- ECPG United States
- SYRE United States
- Employees
- ECPG N/A
- SYRE N/A
- Industry
- ECPG Finance Companies
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- ECPG Finance
- SYRE Health Care
- Exchange
- ECPG Nasdaq
- SYRE Nasdaq
- Market Cap
- ECPG 905.2M
- SYRE 1.1B
- IPO Year
- ECPG 1999
- SYRE 2016
- Fundamental
- Price
- ECPG $36.64
- SYRE $16.18
- Analyst Decision
- ECPG Strong Buy
- SYRE Buy
- Analyst Count
- ECPG 3
- SYRE 5
- Target Price
- ECPG $62.67
- SYRE $55.00
- AVG Volume (30 Days)
- ECPG 239.6K
- SYRE 554.6K
- Earning Date
- ECPG 08-06-2025
- SYRE 08-05-2025
- Dividend Yield
- ECPG N/A
- SYRE N/A
- EPS Growth
- ECPG N/A
- SYRE N/A
- EPS
- ECPG N/A
- SYRE N/A
- Revenue
- ECPG $1,380,750,000.00
- SYRE N/A
- Revenue This Year
- ECPG $21.70
- SYRE N/A
- Revenue Next Year
- ECPG $8.86
- SYRE N/A
- P/E Ratio
- ECPG N/A
- SYRE N/A
- Revenue Growth
- ECPG 11.49
- SYRE N/A
- 52 Week Low
- ECPG $26.45
- SYRE $10.91
- 52 Week High
- ECPG $51.77
- SYRE $40.26
- Technical
- Relative Strength Index (RSI)
- ECPG 39.92
- SYRE 47.85
- Support Level
- ECPG $35.67
- SYRE $15.81
- Resistance Level
- ECPG $38.20
- SYRE $17.70
- Average True Range (ATR)
- ECPG 1.14
- SYRE 0.94
- MACD
- ECPG -0.25
- SYRE -0.10
- Stochastic Oscillator
- ECPG 22.44
- SYRE 14.83
About ECPG Encore Capital Group Inc
Encore Capital Group Inc is an international specialty finance company. It provides debt recovery solutions for consumers and property owners across a broad range of financial assets. The company purchases portfolios of defaulted consumer receivables at deep discounts to face value and manages them by working with individuals as the consumers repay their obligations and work toward financial recovery. Encore has only a reportable segment portfolio purchasing and recovery.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.